Fibrinogen, Human

Summary

Fibrinogen, Human (CHEMBL2109072) is a phase-3 clinical-stage unknown (ATC B02BB01); indicated across 11 conditions including heart disorder and injury.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• ATC class: B02BB01
• Indications: 11 conditions
• Clinical trials: 45

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109072
Name	Fibrinogen, Human
Type	Unknown
Max phase	3
ATC	B02BB01

Also known as: Evarrest, Factor i (fibrinogen), Factor i human, Fibrinogen, Fibrinogen (human), Fibrinogen concentrate (human), Fibrinogen concentrate human, Fibrinogen human, Fibrinogen human plasma-derived, human, Haemocomplettan p, Human fibrinogen

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

11 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
heart disorder	3	MONDO:0005267	EFO:0003777
injury	3	MONDO:0021178	EFO:0000546
liver disorder	3	MONDO:0005154	EFO:0001421
congenital afibrinogenemia	3	MONDO:0008737	MONDO:0008737
hematologic disorder	2	MONDO:0005570	HP:0001871
congenital heart disease	2	MONDO:0005453	EFO:0005207

5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 45.

Phase distribution

Phase	Trials
PHASE4	13
Not specified	11
PHASE2	10
PHASE3	7
PHASE1/PHASE2	3
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00290836	PHASE4	COMPLETED	Assess Efficacy and Safety of TachoComb H vs. Standard Surgical Treatment (i.e. Suturing) in Patients Undergoing Prostatectomy (TC-017-AU)
NCT00440401	PHASE4	COMPLETED	TachoSil® Versus Standard Haemostatic Treatment of Haemorrhage in Cardiovascular Surgery (TC-023-IM)
NCT00983112	PHASE4	UNKNOWN	Evicel Study on the Peri-operative Bleeding in Total Knee Prothesis Surgery
NCT00994045	PHASE4	COMPLETED	Fibrinogen as an Alternative to FFP in Aortic Surgery.
NCT02299947	PHASE4	TERMINATED	Bloodtranfusions After Aortic Surgery
NCT02864875	PHASE4	COMPLETED	Early Administration of Fibrinogen in Polytraumatized Patients With Hypofibrinogenemia: a Randomized Feasibility Trial
NCT03014700	PHASE4	COMPLETED	Fibrinogen Concentrate vs Cryoprecipitate
NCT03183479	PHASE4	COMPLETED	The Effects of Fibrinogen Concentrate Infusion on Blood Loss and Allogeneic Blood Conservation in Scoliosis Surgery
NCT03269955	PHASE4	UNKNOWN	The Effect of Application of TachoSil® in Pancreatoduodenectomy
NCT03884725	PHASE4	UNKNOWN	Fibrinogen Concentrate In Children Cardiac Surgery 2
NCT04376762	PHASE4	COMPLETED	Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients
NCT04534751	PHASE4	UNKNOWN	Factor In the Initial Resuscitation of Severe Trauma 2 Patients
NCT05391412	PHASE4	UNKNOWN	Effect of Prophylactic Fibrinogen Concentrate In Scoliosis Surgery
NCT05449834	PHASE3	RECRUITING	Fibrinogen Early In Severe Trauma StudY II
NCT00241163	PHASE3	COMPLETED	TachoComb S Versus Standard Surgical Treatment in Surgical Resection of Renal Tumour (TC-015-IN)
NCT00293514	PHASE3	COMPLETED	TachoSil Versus Standard Surgical Treatment for Air Leakage in Pulmonary Lobectomy (TC-021-IM)
NCT01359878	PHASE2/PHASE3	COMPLETED	Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial
NCT01471730	PHASE3	COMPLETED	The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery
NCT01539057	PHASE3	UNKNOWN	The Efficacy of the Administration of Fibrinogen in Liver Transplantation
NCT01623531	PHASE3	COMPLETED	Prospective Double Blinded Randomized Control Study of the Use of Fibrinogen in High-Risk Cardiac Surgery
NCT05300672	PHASE3	COMPLETED	Fibrinogen Replacement to Prevent Intracranial Haemorrhage in Ischemic Stroke Patients After Thrombolysis (FibER)
NCT00493272	PHASE1/PHASE2	COMPLETED	Dilutional Coagulopathy in Patients Undergoing Elective Surgery
NCT00968045	PHASE2	COMPLETED	Fibrinogen and Bleeding After Cardiac Surgery
NCT01187225	PHASE2	COMPLETED	Fibrinogen Concentrate In Children After Cardiac Surgery
NCT02117349	PHASE2	TERMINATED	Topical Raplixa for Surgical Bleeding in Children
NCT02203968	PHASE1/PHASE2	COMPLETED	Fibrinogen in the Initial Resuscitation of Severe Trauma (FiiRST)
NCT02344069	PHASE2	COMPLETED	Pilot Randomized Trial of Fibrinogen in Trauma Haemorrhage
NCT02528708	PHASE1/PHASE2	WITHDRAWN	A Program to Evaluate Riastap® and FIBTEM® for the Early Control and Treatment of Postpartum Hemorrhage (PERFECT PPH)
NCT02542306	PHASE2	UNKNOWN	Safety and Efficacy of Fibrinogen Concentrate in Aortic Arch Surgery Involving Moderate Hypothermic Circulatory Arrest
NCT02745041	PHASE2	COMPLETED	Fibrinogen Early In Severe Trauma studY
NCT03508141	PHASE2	UNKNOWN	Fibrinogen Early In Severe Trauma studY Junior
NCT04434001	PHASE2	TERMINATED	ZEPLAST- PED: ZEro_PLASma Trial in Small Infants Undergoing Cardiac Surgery
NCT04807621	PHASE2	UNKNOWN	Platelets or Fibrinogen as First-line Treatment for Bleeding During Pedatric Heart Surgery
NCT05091684	PHASE2	TERMINATED	Administration of Fibrinogen Concentrate for Refractory Bleeding
NCT06582420	Not specified	NOT_YET_RECRUITING	Pre-hospital Administration of Fibrinogen in Trauma-Induced Coagulopathy
NCT00279383	Not specified	COMPLETED	OSHES - Observational Study on Hemostasis in Surgery (TC-022-IT)
NCT00285623	Not specified	COMPLETED	Observational Cohort Study of TachoSil (TC-018-IN)
NCT00546169	Not specified	COMPLETED	Non-interventional Trial About Treatment of Haemorrhages in Cholecystectomy With TachoSil (TC-027-DE)
NCT00713596	Not specified	TERMINATED	Study Evaluating Benefit of Using Fibrin Glue in Septorhinoplasty
NCT03723200	Not specified	COMPLETED	Analyzes of Hemorrhagic Obstetric Patients Whose Were Used Fibrinogen

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).